173 related articles for article (PubMed ID: 9607579)
1. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
2. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J
J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
4. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
7. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
[TBL] [Abstract][Full Text] [Related]
8. Tumor metabolic rates in sarcoma using FDG PET.
Eary JF; Mankoff DA
J Nucl Med; 1998 Feb; 39(2):250-4. PubMed ID: 9476930
[TBL] [Abstract][Full Text] [Related]
9. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
10. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
11. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
13. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
[TBL] [Abstract][Full Text] [Related]
14. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
15. Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas.
Rusten E; Rødal J; Revheim ME; Skretting A; Bruland OS; Malinen E
Acta Oncol; 2013 Aug; 52(6):1160-7. PubMed ID: 23198721
[TBL] [Abstract][Full Text] [Related]
16. Intense accumulation of 18F-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors.
Park JH; Park EK; Kang CH; Kim CH; Choe JG; Noh W
Ann Nucl Med; 2009 Dec; 23(10):887-9. PubMed ID: 19862481
[TBL] [Abstract][Full Text] [Related]
17. Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue sarcomas.
Conrad EU; Morgan HD; Vernon C; Schuetze SM; Eary JF
J Bone Joint Surg Am; 2004; 86-A Suppl 2():98-104. PubMed ID: 15691114
[No Abstract] [Full Text] [Related]
18. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
Eary JF; O'Sullivan F; Powitan Y; Chandhury KR; Vernon C; Bruckner JD; Conrad EU
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1149-54. PubMed ID: 12192559
[TBL] [Abstract][Full Text] [Related]
19. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
[TBL] [Abstract][Full Text] [Related]
20. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Bredella MA; Caputo GR; Steinbach LS
AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
